Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto)
A PSMA-targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer.
What is Lutetium Lu 177 Vipivotide Tetraxetan?
What it targets
PSMA is overexpressed on prostate cancer cells. Pluvicto binds PSMA and delivers beta radiation from lutetium-177 directly to PSMA-positive cancer deposits.
Who it may help
Adults with PSMA-positive metastatic castration-resistant prostate cancer who have received prior ARPI therapy, with or without prior taxane chemotherapy.
Why testing matters
A PSMA PET scan must confirm PSMA positivity before treatment. Low or absent PSMA expression reduces expected benefit and may make the patient ineligible.
Which cancers can Lutetium Lu 177 Vipivotide Tetraxetan treat?
Pluvicto is approved and studied in selected prostate cancer settings where PSMA expression is confirmed by PET imaging.
| PSMA-positive mCRPC (post-ARPI and post-taxane) | FDA-approved March 2022 (VISION trial) for adults with PSMA-positive mCRPC who have received prior ARPI therapy and taxane-based chemotherapy. |
| PSMA-positive mCRPC (post-ARPI, chemo-naive) | FDA-approved October 2023 (PSMAfore trial) for adults who progressed on ARPI therapy without prior taxane chemotherapy, with option to switch to docetaxel. |
| Hormone-sensitive prostate cancer | Being studied in clinical trials such as PSMAddition. Routine use is not established — eligibility depends on future regulatory approvals and specialist assessment. |
| Other advanced prostate cancer settings | Earlier treatment lines and new combinations under active investigation. Use in these settings is not yet routine and depends on emerging trial data and future approvals. |
Are you eligible for Lutetium Lu 177 Vipivotide Tetraxetan?
Eligibility for Pluvicto depends on PSMA scan results, treatment history, organ function, and review by both a medical oncologist and nuclear medicine specialist.
- PSMA-positive disease confirmed by a PSMA PET scan such as [68Ga]Ga-PSMA-11 or [18F]DCFPyL
- Metastatic prostate cancer confirmed as castration-resistant on androgen deprivation therapy
- Prior treatment with an androgen receptor pathway inhibitor such as abiraterone or enzalutamide
- Adequate haemoglobin, white blood cell count, and platelet count on baseline CBC
- Adequate kidney function as assessed by the treating nuclear medicine team
- Adequate bone marrow reserve — extensive prior chemotherapy or radiation may affect eligibility
- Performance status suitable for radioligand therapy as assessed by the treating oncologist
- Disease pattern compatible with PSMA-targeted radioligand therapy
- Effective contraception required for men during treatment and for the period advised after
- Joint review and treatment plan by both a medical oncologist and nuclear medicine specialist
How does Lutetium Lu 177 Vipivotide Tetraxetan work?
- PSMA overexpression on prostate cancer cells
- Radioligand design — targeting molecule plus payload
- PSMA binding and cellular delivery
- Beta radiation damages cancer cell DNA
- Reaching systemic metastatic deposits
Pluvicto was the first PSMA-targeted radioligand therapy to demonstrate overall survival benefit in large randomised prostate cancer trials.
Tests required before starting Lutetium Lu 177 Vipivotide Tetraxetan
These tests confirm PSMA positivity, eligibility, organ function, and treatment baselines before Pluvicto can begin.
| PSMA PET Scan | Mandatory before treatment — confirms PSMA-positive disease. Low or absent expression may make the patient ineligible for Pluvicto. |
| CT Scan or MRI | Assesses the extent of metastatic disease, nodal involvement, and soft tissue deposits to support treatment planning. |
| Bone Scan or PET Imaging | Evaluates bone metastasis burden — important for monitoring treatment response and planning supportive care. |
| PSA Level | Baseline PSA is essential for monitoring treatment response at each cycle review; trends over time are more informative than single values. |
| Complete Blood Count (CBC) | Baseline red cells, white cells, and platelets — monitored regularly throughout treatment to detect bone marrow suppression early. |
| Kidney Function Tests | Renal function must be adequate before treatment — kidneys handle lutetium-177 clearance and receive radiation exposure during this process. |
| Liver Function Tests | Hepatic function assessed to confirm safe drug handling and guide supportive care planning during treatment. |
| Performance Status Assessment | Overall fitness and ability to tolerate radioligand therapy is reviewed by both the oncologist and nuclear medicine team before starting. |
How is Lutetium Lu 177 Vipivotide Tetraxetan given?
Pluvicto is given by slow intravenous infusion at a licensed nuclear medicine centre. It is not a tablet or home injection — each dose requires a specialised facility and trained staff.
| Standard dose | 7.4 GBq (200 mCi) given by slow intravenous infusion by trained nuclear medicine staff at a licensed centre |
| Cycle interval | One infusion every 6 weeks |
| Maximum cycles | Up to 6 cycles; treatment may be shortened if cancer progresses or side effects require stopping earlier |
| Administration setting | Must be given at a nuclear medicine centre licensed for therapeutic radiopharmaceuticals by specially trained clinical staff |
| Radiation safety after infusion | Follow all written precautions provided by your centre, including hydration, hygiene protocols, and temporary distance from vulnerable family members |
| Pre-infusion hydration | Adequate fluid intake before and after infusion helps reduce kidney radiation exposure — follow guidance from your nuclear medicine team |
| Rescheduling a missed cycle | Contact your nuclear medicine team immediately if you cannot attend a scheduled infusion — do not rearrange without clinical guidance |
| Duration of therapy | Treatment continues for up to 6 cycles unless disease progresses or side effects require stopping earlier; each case is reviewed individually |
Clinical evidence and benefits of Lutetium Lu 177 Vipivotide Tetraxetan
Pluvicto demonstrated meaningful clinical benefits in large randomised trials across different mCRPC treatment settings.
| VISION trial (post-ARPI and post-taxane) | Significantly improved radiographic progression-free survival and overall survival compared with standard of care in patients with PSMA-positive mCRPC |
| PSMAfore trial (post-ARPI, chemo-naive) | Substantially improved radiographic progression-free survival compared with ARPI switching in chemo-naive PSMA-positive mCRPC patients |
| PSA reduction in treated patients | Meaningful PSA decline observed in a proportion of treated patients, reflecting anti-tumour activity at the molecular level |
| Bone pain improvement | Some patients with bone metastases experience improvement in pain and reduction in bone-related symptoms during Pluvicto treatment |
| Targeted option after hormone-directed therapy | Provides an effective treatment option for patients who have progressed on ARPI-based hormone therapy without requiring immediate chemotherapy |
| Non-chemotherapy systemic approach | Offers a distinct mechanism compared with taxane chemotherapy, giving patients and oncologists an alternative pathway for PSMA-positive advanced prostate cancer |
Individual responses vary based on PSMA expression, disease burden, prior treatments, blood counts, and kidney function. These represent published clinical trial data.
Side effects of Lutetium Lu 177 Vipivotide Tetraxetan
Pluvicto has a different side-effect profile from standard chemotherapy, but blood count suppression and radiation-related effects require careful and regular monitoring throughout treatment.
| Fatigue | Very common — often the most reported symptom during treatment; intensity can vary across cycles |
| Dry mouth (xerostomia) | Common — salivary glands express PSMA and receive radiation exposure; adequate oral hydration helps manage this effect |
| Nausea | Common — anti-nausea medication is usually prescribed to manage this side effect during and after each infusion |
| Low red blood cells (anaemia) | Can cause or worsen fatigue and weakness — haemoglobin monitored at each cycle; transfusion may be needed in severe cases |
| Low white blood cells (neutropenia) | Increases infection risk — CBC monitored regularly; dose interruption may be needed if counts fall significantly |
| Low platelets (thrombocytopenia) | Increases bruising and bleeding risk — platelet count monitored at each review; dose adjustment may be required |
| Kidney function changes | Kidneys handle lutetium-177 clearance and receive radiation exposure during treatment — renal function monitored throughout |
| Loss of appetite | Common — nutritional support and dietary guidance can help maintain adequate intake during treatment |
| Constipation or diarrhoea | Digestive symptoms are common and usually manageable with standard supportive measures prescribed by your care team |
| Weight loss | Can occur during treatment, particularly in combination with appetite loss and fatigue — nutritional monitoring is recommended |
Contact your doctor immediately if you develop:
- Fever or chills, which may suggest serious infection from low white blood cell count
- Unusual bleeding or bruising suggesting very low platelet count
- Severe weakness or shortness of breath suggesting severe anaemia or cardiac effects
- Reduced urination, swelling, or other symptoms suggesting kidney dysfunction
- Severe nausea or vomiting that cannot be controlled with prescribed medication
- Sudden worsening pain or new neurological symptoms requiring urgent assessment
Safety precautions for Lutetium Lu 177 Vipivotide Tetraxetan
Tell your oncologist and nuclear medicine team about all medical conditions, medicines, and supplements before starting Pluvicto.
- Inform your team of any existing kidney disease, as renal function affects treatment eligibility and dose
- Report any history of low blood counts or bone marrow suppression from prior treatment
- Discuss extensive bone marrow involvement with your oncologist before starting treatment
- Provide a full history of prior chemotherapy and radiation therapy, including dates and doses
- Tell your team about any active infection, which may need treatment before Pluvicto can begin
- Report urinary obstruction or difficulty passing urine, as this can worsen radiation exposure to the bladder
- Men must use effective contraception during treatment and for the period advised by the nuclear medicine team
- Avoid prolonged close contact with pregnant women, infants, and young children for the period specified after each dose
- Provide a complete list of all medicines including those that may affect kidney or blood count function
Lutetium Lu 177 Vipivotide Tetraxetan combination treatments
Pluvicto is used alongside ongoing androgen deprivation therapy and may be combined with other agents in specific clinical settings.
| Pluvicto + androgen deprivation therapy | ADT is maintained throughout Pluvicto treatment in mCRPC — maintaining castrate testosterone levels is part of standard management alongside radioligand therapy |
| Pluvicto + ARPI combinations | Being studied in clinical trials — combination with enzalutamide or darolutamide is under evaluation in PSMA-positive prostate cancer to improve outcomes |
| Pluvicto + bone-targeted agents | Denosumab or zoledronic acid may be used alongside Pluvicto to manage bone metastases and reduce skeletal-related events where clinically indicated |
| Sequential use with taxane chemotherapy | Docetaxel before or after Pluvicto depending on prior treatment history, PSMA status, and eligibility criteria at each clinical decision point |
If Lutetium Lu 177 Vipivotide Tetraxetan stops working
Cancer progression after Pluvicto can occur through several mechanisms. Understanding why guides the next treatment decision.
| Loss of PSMA expression | Prostate cancer can downregulate PSMA on cell surfaces under selective pressure from PSMA-targeted therapy, reducing the drug's ability to bind and deliver radiation effectively |
| Clonal heterogeneity | PSMA-negative cell populations may already be present before treatment and can expand during Pluvicto therapy, reducing overall effectiveness over time |
| AR pathway reactivation | Androgen receptor pathway reactivation remains a key driver of prostate cancer progression regardless of PSMA-targeted therapy and must be assessed on progression |
| Cumulative bone marrow toxicity | Bone marrow suppression may accumulate across cycles, preventing further treatment even if the cancer might still respond to additional radioligand therapy |
| Next-line options after progression | Docetaxel or cabazitaxel chemotherapy, PARP inhibitors for eligible mutations, bone-targeted treatments, immunotherapy for rare biomarker-defined cases, or clinical trial participation |
Cost of Lutetium Lu 177 Vipivotide Tetraxetan by country
The total cost of Pluvicto treatment is significantly higher than the drug price alone due to PSMA PET imaging, nuclear medicine infrastructure, radiation safety requirements, and monitoring at each cycle.
| USA | Per-cycle cost is substantial. Insurance coverage may apply for FDA-approved indications. Novartis patient support programs exist for eligible patients — contact the prescribing centre for access details. |
| UK / Europe | Reimbursement varies by country and indication. Available in several EU countries with national health coverage for eligible patients — contact your oncology centre for local availability and reimbursement status. |
| India | Not commercially approved as of 2025-2026. Cost under named-patient or compassionate access at select advanced centres varies significantly. CancerFax can help assess current access options and estimated costs. |
| China | NMPA approval not confirmed as of 2025-2026. Some academic centres run Lu-177 PSMA programs under research protocols — costs and access criteria vary by institution and program. |
| Total cost consideration | Complete Pluvicto treatment includes PSMA PET imaging, nuclear medicine facility fees, radiation safety handling, blood tests, imaging at each cycle, and supportive medications — all contributing to overall cost. |
Availability of Lutetium Lu 177 Vipivotide Tetraxetan globally
Pluvicto is commercially available in FDA- and EMA-approved markets. Access in Asia and other regions varies by regulatory approval, nuclear medicine infrastructure, and radiopharmaceutical supply.
USA
FDA-approved and available at licensed nuclear medicine centres. Novartis patient assistance programs available for eligible patients. Coverage through major insurers and Medicare where applicable.
Europe (EU / UK)
EMA-approved December 2022. Available at qualified nuclear medicine centres across EU and UK. National reimbursement varies by country and indication. Contact your oncology centre for local access details.
India
Not commercially approved as of 2025-2026. Named-patient or compassionate access may exist at select advanced centres. CancerFax can help assess current access options and alternative pathways.
China
NMPA approval not confirmed as of 2025-2026. Select academic hospitals run Lu-177 PSMA programs under research protocols. Specialist assessment at an approved institution is required.
Singapore / South Korea / Israel
Advanced nuclear medicine infrastructure supports access at tertiary oncology centres. Costs and insurance coverage vary by country. CancerFax can assist with coordination and access planning.
Lutetium Lu 177 Vipivotide Tetraxetan in current clinical trials
Pluvicto and PSMA-targeted radioligand therapies are being studied in earlier and new prostate cancer settings beyond the currently approved indications.
| Earlier lines in mCRPC | Trials are studying Pluvicto as a first or second treatment option in mCRPC patients before chemotherapy in a broader population to improve outcomes |
| Hormone-sensitive prostate cancer | PSMAddition and related studies are investigating Pluvicto plus standard of care in metastatic hormone-sensitive prostate cancer to assess benefit earlier in disease |
| Combination with ARPIs and chemotherapy | Trials exploring Pluvicto combined with enzalutamide, darolutamide, and other agents to improve response duration and delay resistance development |
| Dose and schedule optimisation | Studies examining alternative dosing, cycle intervals, and treatment duration to improve tolerability while maintaining clinical efficacy |
| PSMA-expressing non-prostate cancers | Early-phase research exploring Lu-177 PSMA-targeted therapy in other PSMA-expressing tumours including some salivary gland cancers and selected rare tumours |
Your treatment journey with Lutetium Lu 177 Vipivotide Tetraxetan
Diagnosis of advanced prostate cancer
Confirmation of castration resistance
Review of prior hormone therapy and chemotherapy
PSMA PET scan
Blood tests and organ function assessment
Nuclear medicine and oncology review
Radiation safety counselling
Pluvicto infusion
Monitoring after each cycle
PSA, imaging, and response review
Decision on further cycles or next treatment
Questions to ask your oncologist about Lutetium Lu 177 Vipivotide Tetraxetan
- Is my prostate cancer PSMA-positive, and what does that mean?
- Do I need a PSMA PET scan before starting Pluvicto?
- Am I eligible for Pluvicto based on my treatment history?
- Is chemotherapy needed before or after Pluvicto in my case?
- How many cycles of Pluvicto may I need?
- What side effects should I watch for and when should I call my doctor?
- How will my blood counts and kidney function be monitored?
- What radiation safety precautions do I need to follow at home?
- Can Pluvicto help with my bone pain or other symptoms?
- What is the expected cost of Pluvicto in my country?
- Is Pluvicto available near me or in my country?
- What are my options if Pluvicto does not work or stops working?
How CancerFax supports Lutetium Lu 177 Vipivotide Tetraxetan patients
CancerFax helps prostate cancer patients and families understand PSMA-targeted therapy options and navigate access, cost, and specialist connections across countries.
| Report review | Upload your PSMA PET scan report, PSA history, biopsy, and imaging — our oncology team will review and explain implications for Pluvicto eligibility and treatment planning |
| Specialist connection | We connect patients with medical oncologists and nuclear medicine specialists experienced in PSMA-targeted radioligand therapy in India, China, Singapore, and internationally |
| Pluvicto eligibility review | Our team reviews your full treatment history and test results to assess which Pluvicto indication applies and whether you meet all eligibility criteria before you travel or commit to a centre |
| Access in India, China, and other countries | We help patients understand named-patient access, institutional programs, and alternative pathways in countries where Pluvicto is not yet commercially approved |
| Treatment centre coordination | CancerFax coordinates with nuclear medicine and oncology centres for treatment planning, travel logistics, visa, translation, and documentation support for international patients |
| Clinical trial exploration | We identify clinical trials studying Pluvicto and PSMA-targeted therapies that match your eligibility profile, treatment history, and country of treatment, and help initiate contact with study sites |
Frequently asked questions about Lutetium Lu 177 Vipivotide Tetraxetan
Common questions from prostate cancer patients and their families about Pluvicto
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapy that pairs a PSMA-targeting molecule with radioactive lutetium-177 to deliver radiation directly to PSMA-positive prostate cancer cells. Unlike chemotherapy, which broadly attacks rapidly dividing cells throughout the body, Pluvicto homes in on cancer deposits that express PSMA. It is given by intravenous infusion at a specialised nuclear medicine centre, not taken as a tablet at home.
A PSMA PET scan is required before treatment to confirm that your prostate cancer expresses PSMA. Approved scans include [68Ga]Ga-PSMA-11 PET/CT and [18F]DCFPyL PET/CT. If the scan shows low or absent PSMA expression, Pluvicto may not be appropriate. Your oncologist or nuclear medicine specialist will confirm which scan is available at your centre and how to interpret the result.
Yes, in some cases. The original FDA approval in March 2022 (VISION trial) required prior ARPI therapy and taxane chemotherapy. A subsequent approval in October 2023 (PSMAfore trial) extended eligibility to patients with PSMA-positive mCRPC who received prior ARPI therapy but had not yet received chemotherapy. Your oncologist will confirm which indication applies based on your treatment history, PSMA scan result, and organ function.
After each infusion you remain radioactive for several days. Standard precautions include flushing the toilet twice after use, thorough handwashing, and avoiding prolonged close contact with pregnant women, infants, and young children. You may be advised to sleep separately for a specified period. Your nuclear medicine team will provide detailed written radiation safety instructions before you leave the hospital after each cycle.
Response is typically assessed after two or three cycles, approximately three to four months into treatment. Assessment includes PSA levels, imaging such as CT, bone scan, or PSMA PET, and symptom review. Some patients experience early PSA fluctuations that do not indicate treatment failure. Your oncologist will review all available markers together and no single result should be interpreted in isolation.
If prostate cancer grows after Pluvicto, your oncologist will reassess with imaging, PSA measurement, and a review of symptoms and performance status. Next options may include docetaxel or cabazitaxel chemotherapy, PARP inhibitors for patients with eligible mutations, bone-targeted treatments, immunotherapy for rare biomarker-defined cases, or clinical trials. A specialist second opinion can help identify the most appropriate next step.
As of 2025-2026, Pluvicto is not commercially approved in India or China. In India, named-patient or compassionate access may be available at select advanced centres. In China, some academic hospitals run Lu-177 PSMA programs under research protocols. Access requires specialist assessment. CancerFax can help evaluate current access options and alternative pathways in both countries.
The two most important safety warnings for sacituzumab govitecan are severe neutropenia (dangerously low white blood cells) and severe diarrhea, both of which can be life-threatening if untreated. You should contact your oncology team immediately if you develop fever, chills, severe diarrhea, signs of infection, or difficulty breathing. Regular blood count monitoring is required throughout treatment to catch neutropenia early.